How big is OPKO Health, Inc.?

As of Jun 18, OPKO Health, Inc. has a market capitalization of 1,061.48 million and reported net sales of 689.37 million with a net profit of -39.02 million over the latest four quarters. Shareholder's funds are 1,365.45 million, and total assets amount to 2,200.21 million.

As of Jun 18, OPKO Health, Inc. has a market capitalization of 1,061.48 million, categorizing it as a Micro Cap company.<BR><BR>As of Jun 18, the sum of net sales for the latest four quarters is 689.37 million, while the sum of net profit for the same period is -39.02 million.<BR><BR>As of Dec 24, the shareholder's funds are reported at 1,365.45 million, and total assets amount to 2,200.21 million.

What does OPKO Health, Inc. do?

OPKO Health, Inc. is a micro-cap healthcare company in the Pharmaceuticals & Biotechnology sector, reporting net sales of $150 million and a net loss of $68 million as of March 2025. The company has a market cap of approximately $1.06 billion and does not pay dividends.

Overview:<BR>OPKO Health, Inc. is a healthcare company operating in the Pharmaceuticals & Biotechnology industry, categorized as a micro-cap company.<BR><BR>Financial Snapshot:<BR>- Net Sales: 150 Million (Quarterly Results - Mar 2025)<BR>- Net Profit: -68 Million (Quarterly Results - Mar 2025)<BR>- Market cap: USD 1,061.48 Million (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: NA (Loss Making)<BR>- Industry P/E: NA<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: 0.01<BR>- Return on Equity: -3.42%<BR>- Price to Book: 0.81<BR><BR>Contact Details:<BR>- Address: 4400 Biscayne Blvd, MIAMI FL: 33137<BR>- Tel: ['1 305 5754181', '1 310 6917100']<BR>- Website: http://www.opko.com

Should I buy, sell or hold OPKO Health, Inc.?

Who are in the management team of OPKO Health, Inc.?

As of March 2022, the management team of OPKO Health, Inc. includes Dr. Phillip Frost (Chairman and CEO), Dr. Jane Hsiao (Vice Chairman and CTO), Dr. Jon Cohen (Executive Chairman of BioReference Laboratories), and Mr. Steven Rubin (Executive VP - Administration), along with several Independent Directors. This team offers a diverse range of expertise to the company.

As of March 2022, the management team of OPKO Health, Inc. includes:<BR><BR>- Dr. Phillip Frost, who serves as the Chairman of the Board and Chief Executive Officer.<BR>- Dr. Jane Hsiao, who is the Vice Chairman of the Board and Chief Technical Officer.<BR>- Dr. Jon Cohen, who is the Director and Executive Chairman of BioReference Laboratories.<BR>- Mr. Steven Rubin, who holds the position of Executive Vice President - Administration and Director.<BR>- Dr. Robert Fishel, Dr. Anthony Japour, Dr. Richard Krasno, Dr. Richard Lerner, and Dr. Roger Medel, all of whom are Independent Directors. <BR><BR>This team brings a diverse range of expertise to the company.

Is OPKO Health, Inc. overvalued or undervalued?

As of February 24, 2022, OPKO Health, Inc. is considered a risky investment due to its overvaluation indicated by a Price to Book Value of 0.85, a negative EV to EBITDA ratio of -6.52, and poor stock performance with a 1-year return of -6.79% compared to the S&P 500's 17.14%.

As of 24 February 2022, the valuation grade for OPKO Health, Inc. has moved from attractive to risky, indicating a deterioration in its investment appeal. The company appears to be overvalued based on its current financial metrics, particularly with a Price to Book Value of 0.85 and an EV to Sales ratio of 1.64. Additionally, the EV to EBITDA ratio stands at -6.52, reflecting significant operational challenges.<BR><BR>In comparison to its peers, OPKO Health, Inc. has a notably negative EV to EBITDA ratio of -7.2480, while Hims & Hers Health, Inc. is considered expensive with a P/E ratio of 54.7633, and RadNet, Inc. shows a risky valuation with a P/E of 123.7949. The company's recent stock performance has been lackluster, with a 1-year return of -6.79% compared to the S&P 500's 17.14%, further reinforcing the notion that OPKO Health, Inc. is overvalued in the current market environment.

Is OPKO Health, Inc. technically bullish or bearish?

As of October 3, 2025, OPKO Health, Inc. shows a mildly bullish trend supported by positive MACD and Bollinger Bands, although daily moving averages are mildly bearish, and while it has outperformed the S&P 500 recently, it has underperformed over the longer term.

As of 3 October 2025, the technical trend for OPKO Health, Inc. has changed from sideways to mildly bullish. The weekly MACD is bullish, and the monthly MACD is mildly bullish, supporting the positive outlook. Bollinger Bands are bullish on both weekly and monthly time frames. The Dow Theory also indicates a mildly bullish stance on both weekly and monthly charts. However, the daily moving averages are mildly bearish, which adds some caution to the overall bullish sentiment.<BR><BR>In terms of returns, OPKO Health has outperformed the S&P 500 over the past week and month, with returns of 7.48% and 17.04% respectively, compared to the S&P 500's 1.09% and 4.15%. However, the longer-term performance shows significant underperformance over the 3-year and 5-year periods. Overall, the current technical stance is mildly bullish, driven by the positive indicators despite some mixed signals in the moving averages.